Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9691485 | 0.86 | USP2 (0.30) | — | |
| SCHEMBL9691490 | 0.86 | USP2 (0.30) | — | |
| SCHEMBL4401997 | 0.74 | — | — | |
| SCHEMBL14779490 | 0.74 | POLB (0.31) | POLBMAPT | |
| SCHEMBL5491921 | 0.74 | — | — | |
| SCHEMBL24716832 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL12705404 | 0.74 | — | — | |
| SCHEMBL12556815 | 0.74 | — | — | |
| SCHEMBL12972229 | 0.74 | — | — | |
| SCHEMBL12929962 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230151159-A1 | COMPOUND FOR FORMING HARDMASK, HARDMASK COMPOSITION INCLUDING THE COMPOUND, AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE HARDMASK COMPOSITION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-10821110-B2 | Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | HYUNDAI PHARM CO., LTD. (KR) | 2020-11-03 | — | — | US | disclosed |
| US-10822365-B1 | SGLTS inhibitor and application thereof | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2020-11-03 | — | — | US | disclosed |
| WO-2020216350-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2020-10-29 | — | — | WO | disclosed |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-10-22 | — | — | US | disclosed |
| US-10781177-B2 | Pyridine compound and use thereof | NIPPON SODA CO., LTD. (JP) | 2020-09-22 | — | — | US | disclosed |
| EP-2987791-B1 | 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, SUITABLE FOR PREVENTING AND TREATING METABOLIC DISEASES | HYUNDAI PHARM CO LTD (KR) | 2019-07-17 | — | — | EP | disclosed |
| US-20080292707-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER INC | 2008-11-27 | — | — | US | disclosed |
| US-20080292707-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER INC | 2008-11-27 | — | — | US | disclosed |
| US-7414058-B2 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2008030579-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | BIOGEN IDEC MA INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070148236-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER PRODUCTS INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070148236-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | PFIZER PRODUCTS INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070142420-A1 | 4-HETEROARYL-TETRAHYDROQUINOLINES AND THEIR USE AS INHIBITORS OF THE CHOLESTERIN-ESTER TRANSFER PROTEIN | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142420-A1 | 4-HETEROARYL-TETRAHYDROQUINOLINES AND THEIR USE AS INHIBITORS OF THE CHOLESTERIN-ESTER TRANSFER PROTEIN | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-21 | — | — | US | disclosed |
| WO-2005117869-A1 | COMBINATIONS COMPRISING (S)-AMLODIPINE AND A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION | SEPRACOR INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822365-B1 | SGLTS inhibitor and application thereof | SLC5A1, SLC5A2, SLC5A11 | POLB 4870/4885MAPT 855/4885 |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | POLB 3447/4885MAPT 882/4885 |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SLC5A1, SLC5A2, SLC5A11 | POLB 4870/4885MAPT 855/4885 |
| US-10781177-B2 | Pyridine compound and use thereof | NOX1, NOXO1, NOX4 | POLB 4829/4885MAPT 64/4885 |
| US-20070148236-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | ABCG2, ALB, SLCO1A2 | POLB 4735/4885MAPT 280/4885 |
| US-20070142420-A1 | 4-HETEROARYL-TETRAHYDROQUINOLINES AND THEIR USE AS INHIBITORS OF THE CHOLESTERIN-ESTER TRANSFER PROTEIN | CETP, HMGCR, CHLSN | POLB 3312/4885MAPT 3342/4885 |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | HCRTR1, HCRTR2, CRHR1 | POLB 4027/4885MAPT 817/4885 |
| US-10821110-B2 | Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | SLC5A2, SLC5A1, DPP4 | POLB 4651/4885MAPT 2418/4885 |
| US-20080292707-A1 | Pharmaceutical Compositions of Adsorbates of Amorphous Drug | ABCG2, ALB, SLCO1A2 | POLB 4735/4885MAPT 280/4885 |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | ADORA2A, ADORA3, ADORA2B | POLB 2948/4885MAPT 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.